Tactical Therapeutics

Executive Summary

Tactical Therapeutics is a private biotechnology company pioneering first-in-class small molecule inhibitors that target calcium signaling pathways to overcome treatment resistance in solid tumors, with a primary focus on glioblastoma (GBM). The company's approach addresses a critical unmet need, as current therapies for GBM are limited and resistance is almost universal. By disrupting calcium-mediated survival signals, Tactical's lead candidate aims to sensitize tumors to standard therapies and impede progression. The platform has potential applicability beyond GBM to other resistant solid cancers, offering a differentiated mechanism that could complement existing immunotherapies and chemotherapies. Preclinical data have demonstrated target engagement and anti-tumor activity in relevant models, supporting advancement toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026IND Submission for Lead Candidate in Glioblastoma65% success
• Q4 2026Presentation of Preclinical Data at Major Oncology Conference70% success
• Q1 2027Potential Strategic Partnership or Licensing Deal30% success